Publication | Closed Access

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection

Hiv-1 ProteasePharmacologyAntiviral TherapySymptomatic Hiv InfectionPharmacotherapyAntiviral DrugHivMedicine